AIkido Pharma Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Anthony C. Hayes
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- ONE ROCKEFELLER PLAZA, 11TH FLOOR New York City NY United States of America 10020
- IPO Date
- Mar 18, 1980
- CIK
- 0000012239
- Website
- aikidopharma.com
- Similar Companies
- Business
- AIkido Pharma Inc. (Nasdaq: AIKI) is a biotechnology company focused on developing small-molecule anti-cancer therapeutics and antiviral agents. The company maintains a diverse pipeline targeting prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL), including preclinical candidates such as DHA-dFdC for pancreatic cancer and KPC34 for AML and ALL; it also advances a broad-spectrum antiviral platform licensed exclusively worldwide from the University of Maryland Baltimore, designed to inhibit replication of viruses including influenza, SARS-CoV-2, Ebola, and Marburg. Founded in 1967 and headquartered in New York City, New York, AIkido Pharma leverages patented technologies through partnerships with institutions such as the University of Texas, Wake Forest University, and the University of Maryland Baltimore, with research activities spanning the United States including South Carolina and Maryland. In December 2022, the company rebranded to Dominari Holdings Inc. (Nasdaq: DOMH) as part of a strategic pivot to diversify beyond biotechnology into financial services via its subsidiary Dominari Financial Inc., which acquired a registered broker-dealer business after deploying approximately $3.2 million in capital; the legacy AIkido Pharma biotech operations continue under AIkido Labs Inc. as successor entity, emphasizing oncology and antivirals amid ongoing share repurchase programs and capital market activities.
Why Is AIkido Pharma (AIKI) Stock Up 1,400%?
Aikido Pharma (AIKI) Stock Price: 1-For-17 Reverse Split Goes Into Effect
Trending Penny Stocks to Watch After Holiday Season
5 Top Penny Stocks To Watch Under $1 After CSCW Stock Explodes
Best Penny Stocks to Buy Right Now? 3 to Watch This Month
Best Penny Stocks to Buy in November? 3 You Need to Know About
Trump-Linked SPAC Has Traders Also Focused On These 6 Stocks
5 Top Penny Stocks Analysts Say To Buy Now With 123%-733% Targets
AIkido Pharma Trading 30% Below Cash Value Despite Positive Indications
Top Penny Stocks to Watch As October Gets Off to a Bullish Start
5 Penny Stocks To Watch Under $1 After CEI Stock's 900% Rally
AIkido Pharma Secures Interest in Electric Truck Maker, Tevva Motors Ltd
Are Biotech Penny Stocks Worth Buying? Check These 3 Out
AIkido Pharma Secures Interest in Growing Tele-health Company
AIkido Provides Update on Use of Machine Learning in Drug Development Program
Notice of Allowance Issued for Central Nervous System Peptide Technology
AIkido Pharma Issues Update on Antiviral Platform with the University of Maryland
AIkido Pharma to Attend the Alzheimer's Association International Conference
AIkido Pharma Files Patent Application for the Use of Ketamine to Treat Alzheimer's Disease
AIkido Pharma Announces Positive Phase 1 Data Presented at ASCO on 225Ac-J591